Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.

By Kyndi M.   Sørensen F. B.   Knudsen H.   Overgaard M.   Nielsen H. M.   Andersen J.   Overgaard J.  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 591-599

Informa Healthcare

Access to resources Recommend Favorite

Tamoxifen in High-risk Premenopausal Women with Primary Breast Cancer Receiving Adjuvant Chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B Trial

By Andersson M.   Kamby C.   Jensen M.-B.   Mouridsen H.   Ejlertsen B.   Dombernowsky P.   Rose C.   Cold S.   Overgaard M.   Andersen J.   Kjaer M.  

European Journal of Cancer, Vol. 35, Iss. 12, 1999-11 ,pp. : 1659-1666

Elsevier

Access to resources Recommend Favorite

Postmastectomy radiotherapy in breast cancer with high risk of relapse: current and future approaches

By Gez Eliahu  

Future Oncology, Vol. 1, Iss. 6, 2005-12 ,pp. : 767-769

Future Medicine

Access to resources Recommend Favorite

Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population

By Howard Eugene M.   Lau Stephen K.   Lyles Robert H.   Birdsong George G.   Tadros Talaat S.   Umbreit Jay N.   Kochhar Ruby  

International Journal of Clinical Oncology, Vol. 9, Iss. 3, 2004-06 ,pp. : 154-160

Springer Publishing Company

Access to resources Recommend Favorite

Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

By Andersen Jørn   Kamby Claus   Ejlertsen Bent   Cold Søren   Ewertz Marianne   Jacobsen Erik   Philip Preben   Møller Knud   Jensen Disa   Møller Susanne  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 718-724

Informa Healthcare

Access to resources Recommend Favorite